<DOC>
	<DOCNO>NCT02263950</DOCNO>
	<brief_summary>This clinical trial ass whether medicine call artemether , currently use low dose treat malaria , could also useful treat cancer . For trial , medicine give new way , spray tongue . This delivery several advantage , include good absorption body may easier people take . It prescribe consent patient advance solid tumour , every day 4 month , either twice day . ( For study 'advanced tumour ' mean effective standard therapy option available patient ) . The dose decide Phase 1 study initially test 3 different dos medicine 21 different cancer patient , make sure toxic cause side effect . After , high safe dose identify first phase test 66 cancer patient Phase 2 study , see medicine able reduce size tumour slow growth .</brief_summary>
	<brief_title>A Phase 1/2a Study LON002 Subjects With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>1 . Subjects 18 year old Screening Visit . 2 . Histologic and/or cytologically confirm diagnosis solid tumour clinical imaging evidence tumour advance effective standard therapy available . 3 . At least one evaluable tumour least 10 mm computerise tomography ( CT ) scan magnetic resonance imaging ( MRI ) pretreatment stage 4 . At least one prior systemic anticancer treatment disease refractory progressive follow treatment . 5 . Eastern Co operative Oncology Group ( ECOG ) performance â‰¤ 2 . 6 . An adequate renal , liver bone marrow function . 7 . Women child bear potential ( WOCBP ) must negative pregnancy test start treatment . 8 . Sexually active woman childbearing potential must use acceptable form contraception , detail protocol . 9 . Male subject must successful vasectomy ( confirm azoospermia ) female partner must meet criterion define protocol ( i.e. , childbearing potential practicing highly effective contraception throughout study period 30 day study drug discontinuation ) . Those partner use hormonal contraceptive must also use additional approve method barrier contraception . 10 . Expected life expectancy &gt; 4 month . 1 . Unwillingness inability provide inform consent . 2 . Any evidence severe uncontrolled systemic disease , infection laboratory find view Investigator make undesirable patient participate trial . 3 . Allergic artemether artemisinin derivative component sublingual formulation . 4 . Pregnancy lactation . 5 . Subject major surgery significant traumatic injury within 4 week start study drug ; subject recover side effect major surgery ( define require general anaesthesia ) subject might require major surgery course study . 6 . Subject anticancer treatment within 4 week start study drug , exclude small field palliative irradiation may perform 2 week prior start study drug . 7 . Subject prior treatment investigational drug within precede 4 week study start .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Malignant Neoplasm</keyword>
	<keyword>Artemether</keyword>
	<keyword>Sublingual</keyword>
	<keyword>Neoplastic disease</keyword>
	<keyword>Solid Tumour</keyword>
	<keyword>Anti-cancer drug</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>LON002</keyword>
</DOC>